PE20070367A1 - Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa - Google Patents

Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa

Info

Publication number
PE20070367A1
PE20070367A1 PE2006000854A PE2006000854A PE20070367A1 PE 20070367 A1 PE20070367 A1 PE 20070367A1 PE 2006000854 A PE2006000854 A PE 2006000854A PE 2006000854 A PE2006000854 A PE 2006000854A PE 20070367 A1 PE20070367 A1 PE 20070367A1
Authority
PE
Peru
Prior art keywords
inhibitors
compounds
secretase enzyme
beta secretase
triazaespiro
Prior art date
Application number
PE2006000854A
Other languages
English (en)
Inventor
Craig A Coburn
Samuel L Graham
Shaun R Stauffer
Wanli Lu
Bruce Fahr
Wenjin Yang
Georgia B Mcgaughey
Melissa S Egbertson
Original Assignee
Merck & Co Inc
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Sunesis Pharmaceuticals Inc filed Critical Merck & Co Inc
Publication of PE20070367A1 publication Critical patent/PE20070367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) O SU TAUTOMERO DE FORMULA (I') DONDE R1 ES H, ALQUILO(C1-C10), CICLOALQUILO(C3-C12), ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON H, HALO, OH, ENTRE OTROS; R2 ES HALO, CN, ALQUILO(C1-C10), ENTRE OTROS; R3 ES H, ALQUILO(C1-C10), FENILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON HALO, OH, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5(R,S),7(R,S)-8-BENCIL-4-(CICLOHEXILAMINO)-1-(3-FLUOROFENIL)-7-METIL-1,3,8-TRIAZAESPIRO[4,5]DEC-3-EN-2-ONA RACEMICA (DIASTEREOMERO A), 5(R,S),7(S,R)-8-BENCIL-4-(CICLOHEXILAMINO)-1-(3-FLUOROFENIL)-7-METIL-1,3,8-TRIAZAESPIRO[4,5]DEC-3-EN-2-ONA RACEMICA (DIASTEREOMERO B), 5(R,S),7(R,S)-4-(CICLOHEXILAMINO)-1-(3-FLUOROFENIL)-8-(3-ISOPROPOXIBENCIL)-7-METIL-1,3,8-TRIAZAESPIRO[4,5]DEC-3-EN-2-ONA RACEMICA (DIASTEREOMERO A), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA BETA SECRETASA SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
PE2006000854A 2005-07-18 2006-07-17 Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa PE20070367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70009005P 2005-07-18 2005-07-18

Publications (1)

Publication Number Publication Date
PE20070367A1 true PE20070367A1 (es) 2007-05-12

Family

ID=37491690

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000854A PE20070367A1 (es) 2005-07-18 2006-07-17 Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa

Country Status (12)

Country Link
US (1) US8211904B2 (es)
EP (1) EP1910364B1 (es)
JP (1) JP2009502786A (es)
CN (1) CN101238124A (es)
AR (1) AR054560A1 (es)
AT (1) ATE550338T1 (es)
AU (1) AU2006270084B2 (es)
CA (1) CA2615656A1 (es)
DO (1) DOP2006000169A (es)
PE (1) PE20070367A1 (es)
TW (1) TW200728305A (es)
WO (2) WO2007011810A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
RU2390350C2 (ru) * 2003-02-01 2010-05-27 Ньюралаб Лимитед Активная иммунизация для создания антител к растворимому а-бета
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2590337C (en) * 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
KR20080025079A (ko) 2005-06-14 2008-03-19 쉐링 코포레이션 아스파르틸 프로테아제 억제제
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EP2063889A4 (en) * 2006-09-07 2009-09-16 Merck & Co Inc SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
US8399473B2 (en) * 2006-10-06 2013-03-19 Merck, Sharp & Dohme, Corp. Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
EP2091328B1 (en) 2006-10-30 2011-12-28 Merck Sharp & Dohme Corp. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008085509A1 (en) * 2007-01-04 2008-07-17 Merck & Co., Inc. Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8158620B2 (en) * 2008-01-18 2012-04-17 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
JP2011519913A (ja) * 2008-05-05 2011-07-14 ファイザー・インク 神経変性疾患治療のための新規なクラスのスピロピペリジン
CA2731209A1 (en) * 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
AR073406A1 (es) * 2008-09-30 2010-11-03 Eisai R&D Man Co Ltd Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
GEP20135806B (en) * 2008-11-23 2013-04-10 Pfizer Lactams as beta secretase inhibitors
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
AU2011227511B2 (en) 2010-03-15 2014-02-20 Amgen Inc. Spiro-tetracyclic ring compounds as Beta - secretase modulators
EP2547686B1 (en) 2010-03-15 2014-01-22 Amgen Inc. Amino-dihydrooxazine and amino-dihydrothiazine spiro compounds as beta-secretase modulators and their medical use
JP2013523806A (ja) 2010-04-09 2013-06-17 ファイザー・インク スルタム化合物
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
US9284296B2 (en) 2010-11-22 2016-03-15 Aubergine Pharmaceuticals Llc Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012100179A1 (en) 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9079919B2 (en) * 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
JP2014524472A (ja) 2011-08-22 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
JP6211509B2 (ja) 2012-03-02 2017-10-11 武田薬品工業株式会社 複素環化合物およびその用途
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8742111B1 (en) * 2013-02-21 2014-06-03 The United States Of America As Represented By The Secretary Of The Army Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016139501A1 (en) * 2015-03-04 2016-09-09 Tfchem Gem difluorocompounds as depigmenting or lightening agents
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP2023516235A (ja) * 2019-12-03 2023-04-19 キャリーオペ，インク． Ｓｓｔｒ５アンタゴニスト

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710504A (en) * 1986-04-04 1987-12-01 Merck & Co., Inc. Anti-depressant spiro hexahydro arylquinolizine derivatives, composition, and method of use therefor
US5221675A (en) * 1989-12-15 1993-06-22 Abbott Laboratories Aza-spirocyclic compounds that enhance cholinergic neurotransmission
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
WO1993004046A1 (en) * 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7439251B2 (en) * 2002-05-03 2008-10-21 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
AU2003276047A1 (en) 2002-06-17 2003-12-31 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
JP2006512404A (ja) 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
AU2003298889A1 (en) 2002-12-04 2004-06-23 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
AU2003296992A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
EP1644322A1 (en) 2003-06-16 2006-04-12 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
AU2005295814A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of Alzhermer's disease

Also Published As

Publication number Publication date
EP1910364B1 (en) 2012-03-21
EP1910364A2 (en) 2008-04-16
WO2007011833A2 (en) 2007-01-25
DOP2006000169A (es) 2007-02-28
WO2007011810A1 (en) 2007-01-25
CN101238124A (zh) 2008-08-06
TW200728305A (en) 2007-08-01
CA2615656A1 (en) 2007-01-25
JP2009502786A (ja) 2009-01-29
US8211904B2 (en) 2012-07-03
ATE550338T1 (de) 2012-04-15
AU2006270084B2 (en) 2011-08-25
AU2006270084A1 (en) 2007-01-25
AR054560A1 (es) 2007-06-27
WO2007011833A3 (en) 2007-03-29
US20070021454A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
TW200505919A (en) DPP-IV inhibitors
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
GEP20146046B (en) Organic compounds
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20091095A1 (es) Moduladores de gamma secretasa
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
PE20040450A1 (es) Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
GB0305152D0 (en) Organic compounds
MA32903B1 (fr) Inhibiteurs de proteine-kinases
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
MX2007013624A (es) Inhibidores de proteina cinasa.
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
PE20060957A1 (es) Compuestos pirazolopiridinas su preparacion y composiciones farmaceuticas
PE20060103A1 (es) Nuevas 5-acilindolinonas con contenido en cicloalquilo y su preparacion como medicamento
RS51144B (sr) Postupak za izradu inhibitora triptaze
PE20091649A1 (es) Derivados de pirrolidinilo
EP2077719A4 (en) BETA-SECRETASE PIPERIDINE AND PYRROLIDINE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Legal Events

Date Code Title Description
FC Refusal